Interferon alpha plus ribavirin tor chronic hepatitis C genotype 1b non-responder patients to interferon alone.

被引：0
|
作者：
Iacono, OL
Castro, A
Diago, M
Cors, R
Borque, MJ
Buey, LG
Monzon, CG
Pedreira, J
Otero, RM
机构：
[1] Univ Autonoma Madrid, Madrid, Spain
[2] Univ Palermo, Madrid, Spain
[3] Hosp Juan Canalejo, A Coru A, Spain
[4] Gen Hosp, Valencia, Spain
[5] Hosp Princess, Madrid, Spain
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
424
引用
下载
收藏
页码：266A / 266A
页数：1
相关论文
共 50 条
  • [21] Early prediction of sustained viral responder and non-responder during interferon and ribavirin combination therapy in chronic hepatitis C
    Nakamura, H
    HEPATOLOGY RESEARCH, 2005, 33 (04) : 269 - 271
  • [22] Retreatment of relapse after interferon therapy for chronic hepatitis C: An international randomized controlled trial of interferon plus ribavirin vs interferon alone.
    Davis, GL
    EstebanMur, R
    Rustgi, V
    Hoefs, J
    Gordon, S
    Trepo, C
    Shiffman, M
    Zeuzem, S
    Craxi, A
    Raffanel, C
    Reindollar, R
    Rizzetto, M
    HEPATOLOGY, 1997, 26 (04) : 476 - 476
  • [23] Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
    Yen, Yi-Hao
    Wang, Jyh-Chwan
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Wang, Jing-Houng
    Hu, Tsung-Hui
    Kee, Kwong-Ming
    Hsiao, Chang-Chun
    Lee, Chuan-Mo
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (07) : 652 - 658
  • [24] Long term response to interferon and ribavirin for hepatitis C in patients previously treated with interferon alone.
    Ismail, MK
    Fleckenstein, JF
    Bockhold, K
    Waters, B
    Riely, CA
    HEPATOLOGY, 1999, 30 (04) : 636A - 636A
  • [25] Consensus interferon for earlier non-responder or relapser patients with chronic hepatitis C.
    Karasu, Z
    Gurakar, A
    Jazzar, A
    Emmett, C
    Hulagu, S
    Wright, H
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [26] Amantadine plus interferon is not effective in non responder to interferon chronic hepatitis C patients.
    Diago, M
    Perez-Anton, C
    García, V
    Carbonell, P
    Cors, R
    Aznar, V
    Martinez, M
    Andreu, J
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [27] Daily use of ribavirin-interferon combination in earlier non-responder or relapser patients with chronic hepatitis C.
    Karasu, Z
    Gurakar, A
    Jazzar, A
    McMillon, G
    Hulagu, S
    Wright, H
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [28] Combination therapy with interferon and ribavirin for treatment of patients with chronic Hepatitis C who have failed therapy with interferon alone.
    Lynch, PJ
    Jacobsmeyer, S
    Quigley, M
    Peters, MG
    HEPATOLOGY, 1998, 28 (04) : 576A - 576A
  • [29] Retreatment of IFN/ribavirin non-responder hepatitis C patients: Benefit of PEG-interferon/ribavirin amantadine.
    Maynard, M
    Ahmed, SNS
    Bailly, F
    Rozier, F
    Benmakhlouf, N
    Bourne-Branchu, V
    Fazly, T
    Nemoz, C
    Adeleine, P
    Pradat, P
    Trepo, C
    HEPATOLOGY, 2004, 40 (04) : 398A - 398A
  • [30] Chronic hepatitis C non responder patients to interferon: Results after stopping one year of interferon plus ribavirin combination.
    Diago, M
    Valeros, MD
    Lujan, M
    Cors, R
    Carbonell, P
    Aznar, V
    Andreu, J
    Garcia, V
    HEPATOLOGY, 1998, 28 (04) : 713A - 713A
12345